UK markets close in 5 hours 3 minutes

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
9.45-0.25 (-2.58%)
At close: 1:37PM EDT
Sign in to post a message.
  • l
    luz
    This is my first operation in ADXN and I won... Now seem I have to pay taxes to take out the money. Can someone explain me if this is true?
  • M
    Mr. Buddah
    Adxt is what you want

    The magnificent one

    Buddah the great
  • P
    Paul R
    Nobody seems to care about this company. Under the radar is an understatement. I am accumulating. Join me for some fun. We can go to Switzerland for the next annual meeting. Beautiful place, I've been there. I see this as a takeover candidate because of their deep pipeline. If there are people that disagree, please post yoir opinion. I am always looking to reevaluate based on new info.
  • P
    Paul R
    Nice move today. Glad I have been accumulating. I hope for one or two more dips before takeoff.
    The Addex pipeline is really strong, and so many drugs are advancing in the pipeline with news soon.
  • P
    Paul R
    Last chance to buy this below $10. Many trial updates are pending.
  • M
    M
    Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
    Thu Jan 21 07:02:03 2021 EDT
    First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021
    Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.

    Pre Market Resistance at 18.20 - then there is little resistance upwards.
  • S
    S
    $ADXN ADXN.S.W TICKER CHF SWISS THIS IS THERE PHARMACEUTICAL STOCK ITS ROCKETING TODAY thats the ticker its there pharmaceutical side look at it already jumped 20%
  • P
    Paul R
    There are a whole lot of ADXN "catalysts" (I hate that word) either imminent or scheduled for Q2. Epilepsy, Parkinson's, twitchy eyelids (don't laugh, that can be a big problem). I think now is a good price and time to accumulate. This Swiss company is flying under the radar but not for much longer I believe.
  • H
    Hokiefun
    This company partnered years back with J and J and actually have very different pipeline. Suppose to be a read out soon.
  • T
    Tim
    What part of the game is this? Got in at $15.50 and thought I was doing something. Feels like it’s being held down. Might have to wait for AH
  • K
    KingBoston!
    3 o’clock sour hour. Can it fill the gap?
  • J
    Jerry
    why no one buys this
  • H
    Hokiefun
    What moving this today? Was going to add to this but had it for the last few years in foreign shares.
  • R
    Reza
    absolutely undervalued because of the current situation in the market.
  • B
    Biotechinvestor
    Check out this youtube video that explains trading biotech stocks with decent strategies and explanations.

    I wish I watched this years ago, it would have save me a lot of time.

    Enjoy

    https://youtu.be/NPnKFYrib5Q
  • S
    S
    They have a breakthrough on parkinsonism disease trial is January 2021
  • P
    Paul R
    Seems like a good buy now after the recent drop due to the offering. Addex has a deep pipeline and now more $ (or actually CHF) to advance it.
  • K
    KingBoston!
    I’m pretty sure Darmesh shorted this when he told his minions to buy this morning
  • m
    mr
    Pre-market was $18.08 so buying anything below is a bonus
  • S
    S
    This is going to rock today